Focused On-demand Library for Netrin-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O95631

UPID:

NET1_HUMAN

Alternative names:

Epididymis tissue protein Li 131P

Alternative UPACC:

O95631; E9KL51

Background:

Netrin-1, also known as Epididymis tissue protein Li 131P, plays a pivotal role in the development of the central nervous system. It guides commissural axons and peripheral motor axons, influencing their direction by either attracting or repelling them through its interaction with DCC or UNC5 receptors, respectively. Its ability to regulate microtubule dynamics via UNC5C and its involvement in dorsal root ganglion axon projection underscore its critical function in neural pathway formation.

Therapeutic significance:

The association of Netrin-1 with diseases such as Mirror movements 4, where it is implicated due to genetic variants affecting its gene, highlights its potential as a target for therapeutic intervention. Understanding the role of Netrin-1 could open doors to potential therapeutic strategies.